Erin Anderson

Erin Anderson is a seasoned professional with a diverse background encompassing corporate strategy, management consulting, life science and healthcare investing, R&D strategy, and scientific research. Currently serving as a Senior Associate at Novo Holdings, Erin previously held managerial roles at Novozymes and worked as a management consultant at The Boston Consulting Group (BCG). She possesses over a decade of experience in biomaterials, controlled drug delivery, and tissue engineering, having conducted research in various scientific domains. During her tenure as a post-doctoral fellow at the Wyss Institute at Harvard, Erin led a team dedicated to pioneering a locally delivered therapy for peripheral vascular disease treatment. Her academic achievements include a Ph.D. in Engineering Sciences and a Master's in Bioengineering from Harvard University. Erin has also pursued executive education through courses at Harvard Business School, including the Commercializing Science Course and a Mini MBA Course at the Harvard Graduate Business Club.